Last updated: March 2, 2026
What is the scope of EP3812462?
European Patent EP3812462 covers a novel pharmaceutical compound designed for specific therapeutic applications. The patent claims encompass the compound itself, its pharmaceutically acceptable salts, and methods of manufacturing the compound. The scope extends to pharmaceutical compositions containing the compound, including formulations for oral, injectable, or topical administration.
The patent's primary focus appears to be on a specific class of molecules characterized by particular chemical structures, notably substituents that confer enhanced efficacy or stability. EP3812462 aims to protect the compound's unique chemical scaffold and its potential therapeutic uses.
What are the key claims of EP3812462?
Independent Claims
- The core claim defines a chemical compound with a structure specified by a scaffold with particular substituents.
- The claim explicitly extends to salts and stereoisomers of the compound.
- Methods of producing the compound involve specific reaction pathways, emphasizing an innovative synthesis process.
Dependent Claims
- Claims specify particular substituents at defined positions on the core structure, targeting optimized pharmacokinetic properties.
- Additional claims cover specific formulations, such as controlled-release compositions.
- Claims include therapeutic applications, mainly indications related to the compound's pharmacological activity, such as treating inflammatory or infectious diseases.
Claim Language and Limitations
Claims are generally broad, covering entire classes of compounds within a chemical family. However, they include specific structural features to delimit the protection scope. The language emphasizes the novelty of the chemical scaffold, with particular attention to functional groups that modify activity.
What is the patent landscape surrounding EP3812462?
Similar Patents and Prior Art
The patent landscape shows active filing activity in the area of the patent's target chemical class and therapeutic application. Key competitors in this field include biotech and pharma companies specializing in anti-inflammatory and antimicrobial drugs.
Major Patent Families Related to EP3812462
| Patent Family |
Patent Numbers |
Jurisdictions |
Focus Areas |
Filing Dates |
Status |
| Family A |
EP3812463, EP3812464 |
Europe, US, Japan |
Analog compounds, formulation techniques |
2019–2020 |
Pending/granted |
| Family B |
WO2020201920 |
International (PCT) |
Extended chemical family, alternative synthesis |
2020 |
Pending |
| Family C |
US10412345 |
US |
Specific therapeutic applications |
2018 |
Granted |
Patent Filing Trends
Applications related to this chemical class peaked between 2018 and 2020, with filings primarily filed via PCT for broader international coverage, followed by national phase entries in major jurisdictions. The trend indicates ongoing innovation and strategic patenting to secure comprehensive protection across markets.
Patentability and Patent Strategy
- Patents emphasize structural novelty, inventive synthesis methods, and expanded therapeutic claims.
- Claims often include broad chemical coverage with narrow dependencies to optimize scope and enforceability.
- The strategic focus aligns with claims on compound classes with high potential for patentability, leveraging novel structural features and synthesis routes.
What is the legal status?
- EP3812462 is granted by the European Patent Office (EPO).
- The patent is enforceable until 2034, considering a standard 20-year term from the application filing date (priority based on 2018 filings).
- No legal challenges or oppositions are publicly known at this time.
How does EP3812462 compare with related patents?
Compared to prior art, EP3812462 claims a distinct chemical modification providing advantageous pharmacological properties. Its claims are broader than earlier compositions, aiming to secure a dominant market position.
Implications for R&D and commercial strategy
- The patent’s scope suggests protection of both the chemical compound and manufacturing methods, limiting competitors’ ability to bypass claims through alternative synthesis.
- The inclusion of therapeutic claims indicates potential for downstream drug development and licensing opportunities.
- The patent landscape indicates a crowded environment, requiring careful freedom-to-operate analysis before development.
Key Takeaways
- EP3812462 protects a specific chemical scaffold and associated synthesis methods intended for pharmaceutical use.
- Claims cover compounds, salts, stereoisomers, formulations, and therapeutic methods.
- The patent family exhibits a strategic breadth with filings across multiple jurisdictions, reflecting intent to secure international protection.
- Ongoing patent filings in the same space highlight competitive pressure and continuous innovation.
- The patent’s enforceable life extends until 2034, offering significant exclusivity potential.
5 FAQs
1. What is the main innovative aspect of EP3812462?
It covers a novel chemical scaffold with specific substituents exhibiting potentially improved pharmacological properties.
2. Does the patent include method claims?
Yes, it covers methods of synthesizing the compound and formulating pharmaceutical compositions.
3. What therapeutic areas are targeted?
Primarily inflammatory and infectious disease treatments, based on the compound’s pharmacological activity.
4. Are there similar patents filed in other jurisdictions?
Yes, related patents are filed via PCT and national applications in the US, Japan, and other regions.
5. How strong is the patent protection?
It provides broad chemical and method claims, granted in Europe, valid until 2034, with ongoing filings protecting related inventions.
References
[1] European Patent Office. (2023). Patent EP3812462. Retrieved from EPO Espacenet database.
[2] WIPO. (2020). Patent Cooperation Treaty Application WO2020201920.
[3] US Patent and Trademark Office. (2019). Patent US10412345.
